What was the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing was to announce the early results and consummation of Cigna's offers to exchange outstanding notes from its subsidiaries for new senior notes issued directly by Cigna Corporation, along with cash. It also reported on the amendments made to the indentures of the existing subsidiary notes.

What are the implications of the Registration Rights Agreement for investors holding the new notes?

The Registration Rights Agreement ensures that holders of the new notes can eventually exchange them for freely tradable registered notes. Cigna committed to facilitating this exchange within one year. If Cigna fails to meet this obligation or other 'Registration Default' conditions, the interest rate on the notes may increase by up to 1.00% per year, providing a potential yield enhancement for noteholders in such scenarios.

Were any covenants or restrictions removed from existing debt as part of this transaction?

Yes, in connection with the consent solicitations, Cigna and its subsidiaries entered into supplemental indentures to eliminate certain covenants, restrictive provisions, reporting requirements, and events of default from the indentures governing the existing subsidiary notes.

CI 8-K: Material Agreements, Financial Events & More

Q: How much new debt did Cigna issue in this transaction?

Cigna issued a significant amount of new debt, totaling approximately $7.2 billion in aggregate principal amount across 23 different series of new senior notes.

Summary

Cigna Corporation (CI) filed an 8-K on October 11, 2019, to report on the early results and consummation of its previously announced offers to exchange outstanding notes from its subsidiaries (Cigna Holding Company, Express Scripts Holding Company, and Medco Health Solutions, Inc.) for new senior notes issued by Cigna Corporation and cash. This transaction involved the issuance of approximately $7.2 billion in aggregate principal amount of new Cigna notes across multiple series with varying maturity dates and interest rates. The exchange also included solicitations to amend the indentures governing the existing notes, leading to the elimination of certain covenants, restrictive provisions, and reporting requirements. Concurrently, Cigna entered into a Registration Rights Agreement to facilitate the future exchange of these newly issued private notes for registered notes, aiming to provide liquidity and ease of transfer for holders. Failure to complete this registered exchange offer within a specified timeframe could trigger additional interest payments on the new notes. This series of transactions signifies a significant step in Cigna's debt management strategy post-acquisition, aimed at simplifying its capital structure and potentially optimizing its financing costs.

Key Highlights

1Cigna completed an early settlement of its exchange offers for subsidiary notes, issuing approximately $7.2 billion in new Cigna Corporation senior notes.
2The new notes have diverse maturity dates ranging from 2020 to 2047 and feature interest rates from 3.000% to 8.300%.
3The exchange offers were coupled with consent solicitations to amend indentures governing existing subsidiary notes, removing certain covenants and reporting obligations.
4A Registration Rights Agreement was entered into, obligating Cigna to register the new notes for resale or conduct a registered exchange offer within one year, with potential penalty interest for defaults.
5The new notes were issued to 'Qualified Institutional Buyers' and certain non-U.S. persons, indicating a private placement under Rule 144A and Regulation S.
6The transaction is part of Cigna's broader debt refinancing and capital structure management efforts.

Cigna Group 8-K Report, Material Agreement (Oct 11, 2019)

Summary

Key Highlights

Frequently Asked Questions